Rhythm Pharmaceuticals (RYTM) Short term Debt (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 4 years of Short term Debt data on file, last reported at $10.1 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $10.1 million, up 537.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (up 537.11% YoY), and the FY2025 annual result was $7.3 million, up 373.46% from the prior year.
• Short term Debt grew to $10.1 million in Q1 2026 per RYTM's latest filing, from $7.3 million in the prior quarter.
• Over five years, Short term Debt peaked at $10.1 million in Q1 2026 and troughed at $1.5 million in Q4 2024.
• A 3-year average of $5.0 million and a median of $4.7 million in 2025 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2025 and 2026: Short term Debt soared 373.46% in 2025, then soared 537.11% in 2026.
• A 3-year view of Short term Debt shows it stood at $1.5 million in 2024, then soared by 373.46% to $7.3 million in 2025, then surged by 38.84% to $10.1 million in 2026.
• Business Quant data shows RYTM's Short term Debt at $10.1 million in Q1 2026, $7.3 million in Q4 2025, and $5.6 million in Q3 2025.